GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (FRA:7AC) » Definitions » EBITDA Margin %

Acarix AB (FRA:7AC) EBITDA Margin % : -1,780.46% (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Acarix AB EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Acarix AB's EBITDA for the three months ended in Sep. 2024 was €-1.55 Mil. Acarix AB's Revenue for the three months ended in Sep. 2024 was €0.09 Mil. Therefore, Acarix AB's EBITDA margin for the quarter that ended in Sep. 2024 was -1,780.46%.


Acarix AB EBITDA Margin % Historical Data

The historical data trend for Acarix AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acarix AB EBITDA Margin % Chart

Acarix AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,278.53 -1,753.05 -1,284.43 -1,266.42 -1,195.52

Acarix AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,043.61 -1,830.48 -914.60 -810.40 -1,780.46

Competitive Comparison of Acarix AB's EBITDA Margin %

For the Medical Devices subindustry, Acarix AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acarix AB's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Acarix AB's EBITDA Margin % falls into.



Acarix AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Acarix AB's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-6.671/0.558
=-1,195.52 %

Acarix AB's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-1.549/0.087
=-1,780.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acarix AB  (FRA:7AC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Acarix AB EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Acarix AB's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acarix AB Business Description

Traded in Other Exchanges
Address
World Trade Center Malmo, Jungmansgatan 12, Malmo, SWE, 211 19
Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96 percent certainty.

Acarix AB Headlines

No Headlines